Blocking malaria transmission to Anopheles mosquitoes using artemisinin derivatives and primaquine: a systematic review and meta-analysis by Solomon Abay
Abay Parasites & Vectors 2013, 6:278
http://www.parasitesandvectors.com/content/6/1/278RESEARCH Open AccessBlocking malaria transmission to Anopheles
mosquitoes using artemisinin derivatives
and primaquine: a systematic review
and meta-analysis
Solomon Mequanente AbayAbstract
Background: Among the currently used drugs in malaria case management, artemisinin derivatives and
primaquine have an impact on the transmissible stages of Plasmodium falciparum. Hence, they reduce the
transmission of the parasite from the patient to the mosquitoes. The present study aimed to assess evidence for
this hypothesis from controlled trials.
Methods: All controlled clinical trials evaluating the transmission blocking activity of artemisinin derivatives and
primaquine with or without other antimalarials were included in this systematic review. PubMed, Google Scholar,
Web of Science, ScienceDirect, Medscape and the Cochrane library were systematically searched without language,
publication status or date restrictions. The literature references were also scanned manually. The last search was run
on July 15, 2013. Search terms included artemisinin derivatives, primaquine, malaria transmission, transmission
blocking/reducing drugs and mosquito infection. The outcome measure was the mosquito infectivity rate after
treatment of patients. Data were compared using odds ratio (OR), in random effects models.
Results: Nine trials with a total of 13,831 mosquitoes were included in the meta-analysis. After combining the trials,
the transmission of P. falciparum to Anopheles mosquitoes were lower in artesunate, artemether-lumefantrine and
primaquine groups as compared with their control counterparts with OR of 0.36 (95% confidence interval (CI), 0.14-0.90),
0.49 (95% CI, 0.31-0.79) and 0.09 (95% CI, 0.01-0.73); respectively. In non-comparative longitudinal studies, the use of a
single-dose of primaquine was shown to deter the transmission of malaria briefly.
Conclusion: Evidence on the transmission blocking effect of artemisinin derivatives and primaquine is conclusive. Trials
evaluating the combined impact of artemisinin derivatives and primaquine on malaria transmission is urgently needed.
Keywords: Malaria transmission blocking, Artesunate, Artemether-lumefantrine, Primaquine, Systematic review,
Meta-analysisBackground
Globally, an estimated 3.3 billion people were at risk of
malaria in 2011, with populations living in sub-Saharan
Africa having the highest risk of malaria infection [1].
Between 2000 and 2010, malaria mortality rates fell by
26% around the world. In the World Health Organization
(WHO) African Region the decrease was 33%. During this
period, an estimated 1.1 million malaria deaths wereCorrespondence: solomonabay@gmail.com
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reproduction in any medium, provided the oraverted globally, primarily as a result of a scale-up of inter-
ventions with a proven track record [2,3]. However, malaria
transmission still occurs in 99 countries around the world,
and the malaria burden continues to cripple health systems
in many African countries. In 2010, this entirely prevent-
able and treatable disease caused an estimated 655,000
deaths worldwide [4].
Proven strategies for malaria control include early treat-
ment of the illness with artemisinin-based combination
therapies (ACTs) [5], intermittent preventive treatment for
pregnant women (IPTP) [6], and using measures thatis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(IRS) or insecticide-treated nets (ITNs) [7]. These tools and
strategies have shown to be effective at contributing to mal-
aria control [8]. Among the drugs used currently in malaria
case management, the ACTs and primaquine have an im-
pact on the transmissible stages of Plasmodium falciparum.
It is assumed that artemisinin derivatives act against young
gametocytes, whereas primaquine acts on mature gameto-
cytes, which are usually present in the circulation at the
time when the patient presents for treatment [9].
Independent reports and a pooled data analysis study
speculated about the malaria transmission reduction by ar-
temisinin derivatives from malaria patients to Anopheles
gambiae, a major malaria vector in Africa [10]. Similarly,
many studies have reflected the impact of primaquine on
malaria transmission from patients to Anopheles stephensi,
a sub-tropical species that predominates in Asia. However,
no systematic analysis has been performed on the transmis-
sion blocking activity of artemisinin derivatives and prima-
quine. The present study attempts to make a systematic
review and meta-analysis of the impact of artemisinin deriv-
atives and primaquine on malaria transmission to the vec-
tor, and to measure whether there are general trends across
the different reports on the change in malaria transmission
due to artemisinin derivatives and primaquine. The study
also explores the reasons for variations across the reports.
Methods
Conduct of systematic review and search strategy
The investigator developed a protocol for this systematic re-
view and conducted it in accordance with the PRISMA (Pre-
ferred Reporting Items for Systematic Review and Meta-
Analyses) statement (Additional file 1: Checklist S1) [11]. A
search was conducted to identify studies assessing malaria
transmission blocking effect of drugs. PubMed, Google
Scholar, Web of Science, ScienceDirect, Medscape and the
Cochrane library were systematically searched without lan-
guage, publication status or date restrictions. Literature ref-
erences were also scanned manually. The last search was
run on July 15, 2013. Search terms included artemisinin de-
rivatives, primaquine, malaria transmission, transmission
blocking/reducing drugs and mosquito infection (Additional
file 2: Table S1). Studies comprising cases of P. falciparum
treated with antimalarials (artemisinin derivatives and/or
primaquine) and evaluating malaria transmission to Anoph-
eles mosquitoes were included. Based on the inclusion cri-
teria, studies for both artemisinin derivative (artesunate and
artemether) and primaquine were selected for qualitative
and quantitative synthesis. Figure 1 outlines the identifica-
tion of studies for this systematic review and meta-analysis.
Inclusion and exclusion criteria
Once it was determined that a paper contained a study
on malaria transmission after interventions (artemisininderivatives or primaquine), the full length article was
consulted to check whether studies fulfill the following
inclusion criteria for the meta-analysis:
i. controlled clinical trial on malaria patients;
ii. study on malaria transmission test from a patient to
mosquito after treating the patient with the existing
antimalarials; and
iii. evaluating mosquito mid-gut for oocyst prevalence
to measure the extent of malaria transmission.
Similar trials with the aforementioned criteria were
also included for the qualitative synthesis. Studies in-
volving laboratory animals or trials without control arms
were excluded in the meta-analysis.
Study design and outcome measures
The endpoints were mosquito infection prevalence out of
all mosquitoes getting a blood-meal on patients after
treatment with antimalarials. The endpoint evaluation was
done in mosquitoes following their blood-meal directly on
patients and artificial membrane feeding apparatus in
primaquine trials and artemisinin derivatives; respectively.
A data extraction sheet was used by the investigator to
calculate the prevalence of mosquito infection in each
trial. Information was extracted from each included trial
on characteristics of trial participants, types of interven-
tion (including type, dose, duration and frequency) and
trial outcomes (mosquito infection prevalence). The odds
of the end points from mosquitoes in the categories of ar-
temisinin derivatives/primaquine and control (standard
drugs) were calculated. The odds ratio (OR) and 95% con-
fidence intervals (CI) for the prevalence of mosquito infec-
tion was then calculated.
The risk of bias in the studies used for meta-analysis
was assessed by the investigator in an un-blinded man-
ner using a tool developed by the Cochrane Collabor-
ation (focusing on specific domains including random
sequence generation, allocation concealment, blinding of
participants and personnel, blinding of outcome assess-
ment, incomplete outcome data, selective reporting)
[12]. Due to the small number of studies identified, trials
were not excluded based on quality assessment. For the
same reason, publication bias was not assessed [12].
Statistical analysis
Meta-analysis was performed using Meta-analyst, a soft-
ware for meta-analysis of binary, continuous and diagnos-
tic data [13]. The random effect method was used to test
for differences in binary outcomes between artemisinin de-
rivatives/primaquine and control (standard drug).
Heterogeneity, the variations among study outcomes,
was checked by tau2 statistic, chi-square based Q-test, I2
statistics and heterogeneity P-value. The author chose the
537 records identified through Pubmed, 
Google Scholar, Web of Science, 
ScienceDirect, Medscape and the 
Cochrane library, and scanning of 
references manually 
31 screened further
13  full-text articles assessed for 
eligibility
18 of records excluded
o 1 population based study
o 1 modeling study
o 10 experimental laboratory 
studies
o 1 review study
o 5 studies speculate the 
transmission reduction based 
on gametocyte carriage
8  studies included in 
qualitative analysis 
(8 full text)*
6 studies included for 
meta-analysis of artesunate and 
artemether-lumefantrine (4 full 
text)
Of records excluded




o 1 study  pooled data from  
different studies without  
heterogeneity test
506 records excluded because they 
did not address the study question
3  studies included for 
meta-analysis of 
primaquine (2 full text)
11 full text
Figure 1 Study selection flow diagram. *three articles were used as sources of data for both qualitative and quantitative synthesis.
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Laird) [14] to calculate the combined OR and 95% CI,
even in a meta-analysis with low level of heterogeneity, in
order to accommodate the random variation within the
studies and the variation between the different studies.
Results
Description of included studies
The literature search identified the transmission blocking
trials at the level of mosquitoes using two artemisinin de-
rivatives (artesunate and artemether) and primaquine. Of
31 potentially relevant publications, only 6 publications(nine studies) on artemisinin derivatives and primaquine,
fulfilled the inclusion criteria for the meta-analysis
(Table 1). Eight publications were qualified for the qualita-
tive analysis of transmission blocking property of prima-
quine and artemisinin derivatives.
Some of the publications, which fulfilled the inclusion
criteria, had results of multiple studies; and these were
used to generate effect sizes for the transmission blocking
property of drugs (artesunate, artemether or primaquine)
vs. controls. The studies used in the quantitative analysis
were from Africa (Gambia and Kenya) and USA dealing
with artemisinin derivatives and primaquine; respectively.
Table 1 Characteristics of trials included in the meta-analysis
Location
(Study year)





Gambia* (2000) Children (1–9 yrs) Artesunate [a] + chloroquine [b]; chloroquine [b] Anopheles gambiae (1208) Membrane feeding [15]
Gambia (1999) Children Artesunate [a] + sulfadoxine-pyrimethamine [f];
sulfadoxine-pyrimethamine [f]
Anopheles gambiae (3192) Membrane feeding [16]
Gambia (1998) Children Artesuante [g] + sulfadoxine-pyrimethamine [f];
sulfadoxine-pyrimethamine [f]
Anopheles gambiae (2688) Membrane feeding [16]
Kenya (2003–4) Children (6 months–10 yrs) Sulfadoxine-pyrimethamine [h] + placebo [i];
artesunate [a] + sulfadoxine-pyrimethamine [h];
sulfadoxine-pyrimethamine [h] + Amodiaquine [j];
artemether-lumefantrine [k]
Anopheles gambiae (3000) Membrane feeding [17]
Gambia (2002) Children (1-10 yrs) Artemether-lumefantrine [c]; chloroquine[d] +
sulfadoxine-pyrimethamine [e]
Anopheles gambiae (540) Membrane feeding [18]
USA** Adults Primaquine [l]; Sulfadiazine + pyrimethamine [m] Anopheles stephensi (30) Direct skin bite [19]
USA*** (1968) Adults (25 to 41 yrs) Primaquine [l]; pyrimethamine [n] Anopheles stephensi (163) Direct skin bite [20]
a = 4 mg/kg for 3 days.
b = 25 mg/kg over 3 days: 10 mg, 10 mg, 5 mg.
c = Each dose: One half-tablet of co-artemether (20 mg artemether + 120 mg of lumefantrine) per 5 kg body weight up to 24 kg (two tablets).
d = Three daily doses of 10 mg/kg.
e = One half-tablet of SP (12.5 mg of pyrimethamine with 250 mg of sulfadoxine per half-tablet).
f = One-half tablet of pyrimethamine-sulfadoxine (12.5 mg pyrimethamine + 250 mg sulfadoxine) for a body weight of 10 kg & a further one-quarter tablet for
each 5 kg increase.
g = 4 mg/kg immediate dose of artesunate.
h = 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine as a single dose plus.
i = placebo once daily for 3 days.
j = 10 mg/kg for once daily for 3 days.
k = administered as half a tablet (20 mg of artemether and 120 mg of lumefantrine) per 5 kg of body weight in a 6-dose.
l = single dose of 45 mg of primaquine base.
m = 500 mg of sulfadiazine every 6 hours for 5 days and 50 mg of pyrimethamine daily for 3 days.
n = Pyrimethamine 50 mg daily for 3 days.
*two parallel studies involving autologous plasma and control serum.
**the study year is not mentioned in the article.
***two parallel studies involving two strains of P. falciparum. Ref. = References.
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A summary of the risk of bias assessment of the con-
trolled trials can be found in Table 2. The extent of risk
of bias varied across the studies. In general, trials done
using artemisinin derivatives had a low risk of bias in
most areas, whereas the trials on primaquine had an un-
clear risk of bias in most areas.Heterogeneity assessment
Heterogeneity among the selected published studies was
examined and the outcomes are presented in Table 3. A
moderate to substantial heterogeneity was observed in the
trials used for the two meta-analyses (with artesunate vs.
without artesunate, primaquine vs. other antimalarials).
The pooled ORs were calculated by the random-effects
model, which assumes that the estimated effect size in dif-
ferent trials follow some distribution [21].Artesunate-based combinations versus antimalarials
without artesunate
The transmission blocking property of artesunate in com-
bination with other antimalarials (chloroquine, sulfadoxine-pyrimethamine alone, sulfadoxine-pyrimethamine with
amodiaquine or with placebo) were compared with the re-
spective standard treatments (controls) without artesunate.
The total number of mosquitoes checked for oocyst were
4,013 in the artesunate group and 6,075 in the control
group. The OR was 0.36 (95% CI, 0.14-0.90), which favours
artesunate-based combination therapy in reducing the
transmission of P. falciparum parasite from patients to
mosquitoes (Figure 2).Artemether-lumefantrine versus other antimalarials
The association between the use of artemether-
lumefantrine and the reduction of malaria transmission
was investigated. The total number of mosquitoes evalu-
ated for oocyst was 1,695 in artemether-lumefantrine
group and 1,845 in control group. The OR was 0.49 (95%
CI, 0.31-0.79), which favours artemether-lumefantrine
therapy in reducing the transmission of malaria from pa-
tients to mosquitoes (Figure 3).
The meta-analysis was in favour of artemisinin deriva-
tives in reducing malaria transmission (Figures 2 and 3).
In two randomised trials, the transmission blocking
























Gambia (2000) low low low low low low unclear [15]
Gambia (1999) low unclear low low low low unclear [16]
Gambia (1998) low unclear low low low low unclear [16]
Kenya (2003–4) low unclear low low low low unclear [17]
Gambia (2002) low low low low low low unclear [18]
USA* high high low low unclear unclear unclear [19]
USA (1968) high high low low unclear unclear unclear [20]
*The study year is not mentioned in the publication. Ref = references.
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ment with artemether-lumefantrine was associated with
a lower proportion of infected mosquitoes as compared
with dihyroartemisinin-piperaquine (OR 0.53; 95% CI,
0.37- 0.77) [22]. The second study comparing
artemether-lumefantrine and artesunate in combination
with sulfadoxine-pyrimethamine did not show any differ-
ence in the proportion of infected mosquitoes (OR 1.60;
95% CI, 0.87-2.98) [17].
Primaquine single dose versus other antimalarials
The association between single-dose primaquine (45 mg)
and malaria transmission blocking from patients to mosqui-
toes was assessed. Overall, 65 mosquitoes in the primaquine
group and 138 mosquitoes in the comparative group were
used. The OR was 0.09 (95% CI, 0.01-0.73), which favours
single-dose primaquine therapy in reducing the transmis-
sion of malaria from patients to mosquitoes (Figure 4).
Single-dose of primaquine and malaria transmission at
different points in time
Single-dose primaquine from 15 mg to 45 mg were given
to individuals diagnosed with P. falciparum, and the pa-
tients were exposed to mosquito bites at different days, i.e.
before and after treatment. The data of mosquito infection
rate versus time (treatment days) from 16 patients,
reported by multiple studies, is presented in Figure 5.
In more than 93% of all the patients, the Plasmodium
transmission to the mosquitoes had been blocked within
the third day of administration of a single dose ofTable 3 Statistics to test heterogeneity in the meta-analysis
Comparison
Tau2 Q-v
With artesunate vs. without artesunate 1.18 79.7
Artemether-lumefantrine vs. other antimalarials 0.05 2.77
Primaquine vs. other antimalarial 1.95 5.15
*For the reasons mentioned in the method (statistical analysis section), random effeprimaquine. However, mosquitoes feeding on patients
after 10 days of treatment became oocyst-positive. Briefly,
this has been revealed in a study that followed patients for
two weeks. Mosquitoes, fed on one patient on the 14th
day and a second patient on the 11th and 15th days after
primaquine treatment, became oocyst-positive (Figure 5).
Addition of primaquine to antimalarials and malaria
transmission: the mefloquine case
Chen and his colleague studied the impact of single-dose
mefloquine with and without primaquine (45 mg) on the
transmission rate of Plasmodium from patients to mos-
quitoes [26]. Before treatment, the mosquito infection
prevalence was similar in mefloquine alone and meflo-
quine plus primaquine arms. Mosquitoes, fed on mem-
brane feeding apparatus containing blood from patients
treated with mefloquine plus primaquine on later days,
were not infected unlike the group treated with meflo-
quine alone that showed a sluggish reduction in infec-
tion rate through time (Figure 6).
In the mefloquine plus primaquine group, the trans-
mission of malaria was blocked throughout the duration
of follow-up, i.e. 3 weeks (Figure 6). This duration of
transmission blockade was longer than the duration
(about 10 days) reported in those studies, which used
only primaquine (Figure 5).
Discussion
Preventing mosquitoes from biting by the existing tools
(e.g. ITNs and IRS) and blocking the transmission ofHeterogeneity Model used for
meta-analysis*alue P heterogeneity I
2 (%)
(df = 5) <0.01 94 Random
(df = 2) 0.25 28 Random
(df = 3) 0.16 42 Random
cts model was chosen for all comparison.
favours  [artesunate] favours [control]
Figure 2 Mosquito infectivity after feeding on blood from patients treated with antimalarials (with vs. without artesunate). *control
serum; **AP = autologous plasma; ***compared with single-dose artesunate; CQ = chloroquine; SP = sulfadoxine-pyrimethamine; AQ = amodiaquine;
AS = artesunate.
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agents (vaccine or drugs) may substantially improve
public health through reducing the burden of malaria
[27]. In areas of stable malaria, a meta-analysis of ITNs on
malaria transmission revealed a reduction by 50% [28].
However, a meta-analysis on existing antimalarials to block
the transmission of the parasite from patients to mosqui-
toes has not yet been done to the author’s knowledge.
The current meta-analysis re-affirmed the advantage of
ACTs in reducing transmission of Plasmodium to the
mosquitoes. In the overall analysis, the odds of transmis-
sion of malaria in artesunate-based combination treatment
group was 2.78 times less than the odds of transmission of
malaria in antimalarials without artesunate (Figure 2).
Similarly, the odds of malaria transmission to mosquitoes
in artemether-lumefantrine treated group was 2 times less
than the odds on other antimalarials used in the studies
(Figure 3). Exceptionally, in one trial [16], the odds of
parasite transmission was higher in artesunate-based com-
bination therapy than the standard therapy without
artesunate. This difference might be attributed to the use
of only one dose of artesunate in the trial.favours [a
Figure 3 Mosquito infectivity after feeding on blood from patients tr
therapy). CQ = chloroquine; SP = sulfadoxine-pyrimethamine; AQ = amodiaFrom the current analysis of the published articles,
artesunate- and artemether-based therapy could reduce
the transmission of the parasite to the mosquitoes. Thus,
these medications, in addition to their role in the clinical
case management of malaria, can have an impact on the
overall transmission rate of malaria and play a role in
controlling malaria.
Primaquine, the old antimalarial drug mainly used in
terminal cure of P. vivax infection, was also tested for its
impact on the transmission of Plasmodium to mosqui-
toes. Trials compared the transmission blocking effect of
single-dose primaquine with the conventional antimalar-
ials: sulfadoxine-pyrimethamine and pyrimethamine.
The current analysis showed that odds of mosquito in-
fection rate was 11 times less for single-dose primaquine
relative to the comparative medicine (Figure 4).
In non-comparative longitudinal trials of single-dose
primaquine, the current systematic review presented the
trends of mosquito infection rate across successive post-
treatment days (Figure 5). There was a rapid drop in mos-
quito infection rate as illustrated in those mosquitoes
feeding on the first and second days post-treatment.rtemether-lumefantrine] favours [control]
eated with artemether-lumefantrine versus control (standard
quine; AL = artemether-lumefantrine.
favours [primaquine]  favours [control]
Figure 4 Mosquito infection prevalence after blood-meal on primaquine treated malaria patients versus control (standard therapy).
PQ = primaquine; SP-1 and 2 = sulfadoxine-pyrimethamine in two independent patient group; P-1 and 2 = treatment in two patients infected with
different strains of P. falciparum.
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as evidenced by the positivity of mosquitoes biting on some
patients after the 10 days of single-dose primaquine therapy.
As the trials employed single-dose primaquine therapy,
which might target only the mature gametocyte [9], the con-
tinuity of transmission blockade by a single dose of prima-
quine fails against the new wave of mature gametocytes that
appear after primaquine has been washed out [29].
The use of single-dose primaquine blocks the transmis-
sion of malaria temporarily (Figure 5). However, combin-
ing it with effective antimalarials - like mefloquine used in
the trial conducted by Chen and his colleague - results in
a disruption of Plasmodium transmission to the vector for
a longer period (Figure 6). This might be explained by the
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Figure 5 Plasmodium infectivity rate to mosquitoes that fed on falcip
Day zero refers to the percent of oocyst positive mosquito fed on patients
positivity of mosquitoes feeding on single patients immediately before trea
of treatment were oocyst positive [19,20,23-25].clearing the parasite, dries out the potential source for a
new wave of gametocytes.
Following the introduction of ACTs in malaria case
management, many researchers report the additional
benefit of ACTs on the partial gametocytocidal effect
compared with the non-ACTs regimens [30-34]. Recently,
there is also interest of combining ACTs with single-dose
primaquine, particularly in areas with a resistant Plasmo-
dium to ACTs or in the phase of malaria elimination. The
addition of primaquine to ACTs results in a further reduc-
tion in gametocyte carriage rate that can have implications
on the extent of malaria transmission [35-39]. However,
the optimal time of administration, treatment duration
and dose of primaquine needs to be understood for im-
proved outcomes. Further studies are also required to9 10 11 12 13 14 15
arum malaria patients treated with a single dose of primaquine.
before the treatment. Sixteen of each line represents the oocyst
























Figure 6 Plasmodium infective rate to mosquitoes after patients
treated with mefloquine alone versus mefloquine plus primaquine.
The mosquitoes fed via membrane feeding on blood of patients
treated with a single dose of mefloquine (750 mg) or a combination
with primaquine single dose (45 mg). MQ =mefloquine; PQ =
primaquine [26].
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addition of primaquine to ACT regimens at the mosquito
level, which is a gold standard approach to evaluate mal-
aria transmission.
The present paper analysed the transmission blocking
activity of artemisinin derivatives and primaquine. The
clinical trials of artemisinin derivatives and primaquine
focused on An. gambiae and An. stephensi; respectively.
None of the identified literatures pertained to other
dominant malaria vectors such as An. funestus and An.
arabiensis [40-42]. In all of the trials included for meta-
analysis, similar colonies of mosquitoes in both interven-
tion and control groups were used. By so doing,
confounding bias related to the variable infection suc-
cess in the different species of vectors could be avoided.
Of course, if the variability in susceptibility of the vec-
tors to P. falciparum infection modified the transmission
blocking activity of drugs, trials with different species of
malaria vectors having a range of infection success
would be required; then systematic reviews should con-
sider subgroup analysis.
Like any retrospective study, this systematic review
has a number of limitations. The literature search might
have missed some trials. The author assumed that miss-
ing reports is unlikely for two reasons. Firstly, a proper
search strategy was followed to identify literatures. Sec-
ondly, the research groups working on transmission
blocking trials at the level of mosquitoes are few. An-
other concern is the comparison of the reference drugs
(artemisinin derivatives and primaquine) with a hetero-
geneous array of antimalarials probably with different
gametocytocidal activity, which in turn might obscure
some systematic differences between drugs. To minimize
these risk, random analytic method was followed in all
data analysis, including in those with little heterogeneity.Conclusions
Based on the data reviewed, artemisinin derivatives
(artesunate and artemether) and primaquine reduce the
transmission of P. falciparum from the patient to the
mosquitoes. Combining the two medications, after a
proper optimization study, might further reduce the
transmission of malaria.
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